Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by UBS Group AG

UBS Group AG increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) by 213.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 576,351 shares of the biopharmaceutical company’s stock after buying an additional 392,760 shares during the quarter. UBS Group AG owned about 0.21% of Amicus Therapeutics worth $7,037,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in FOLD. Van ECK Associates Corp raised its holdings in Amicus Therapeutics by 48.9% during the fourth quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 981 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Amicus Therapeutics by 2.4% in the 3rd quarter. Amalgamated Bank now owns 44,619 shares of the biopharmaceutical company’s stock valued at $466,000 after buying an additional 1,060 shares during the period. ProShare Advisors LLC boosted its stake in shares of Amicus Therapeutics by 2.3% in the third quarter. ProShare Advisors LLC now owns 53,997 shares of the biopharmaceutical company’s stock valued at $563,000 after buying an additional 1,211 shares in the last quarter. Profund Advisors LLC grew its holdings in Amicus Therapeutics by 6.1% during the fourth quarter. Profund Advisors LLC now owns 23,658 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 1,367 shares during the period. Finally, Point72 Hong Kong Ltd lifted its holdings in Amicus Therapeutics by 14.9% in the first quarter. Point72 Hong Kong Ltd now owns 12,685 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 1,646 shares during the period.

Amicus Therapeutics Trading Down 4.9 %

Amicus Therapeutics stock opened at $11.14 on Friday. The stock has a market cap of $3.15 billion, a PE ratio of -15.91 and a beta of 0.81. The company has a current ratio of 2.89, a quick ratio of 2.69 and a debt-to-equity ratio of 3.83. The stock has a 50-day moving average price of $11.44 and a 200 day moving average price of $11.94. Amicus Therapeutics, Inc. has a 52 week low of $7.34 and a 52 week high of $13.84.

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last posted its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). Amicus Therapeutics had a negative net margin of 60.63% and a negative return on equity of 153.68%. The firm had revenue of $88.20 million during the quarter, compared to analyst estimates of $86.95 million. Equities research analysts predict that Amicus Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 11,700 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $11.21, for a total transaction of $131,157.00. Following the transaction, the chief executive officer now directly owns 823,454 shares in the company, valued at $9,230,919.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Bradley L. Campbell sold 11,700 shares of the business’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $11.21, for a total transaction of $131,157.00. Following the completion of the sale, the chief executive officer now directly owns 823,454 shares of the company’s stock, valued at approximately $9,230,919.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman John F. Crowley sold 6,044 shares of the stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $11.34, for a total value of $68,538.96. Following the completion of the transaction, the chairman now directly owns 986,537 shares in the company, valued at $11,187,329.58. The disclosure for this sale can be found here. Insiders have sold 58,028 shares of company stock worth $664,876 over the last quarter. 2.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. UBS Group increased their target price on shares of Amicus Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, March 2nd. StockNews.com started coverage on Amicus Therapeutics in a research report on Thursday, May 18th. They set a “buy” rating on the stock. The Goldman Sachs Group boosted their price objective on shares of Amicus Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, March 2nd. Finally, Bank of America raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.20.

About Amicus Therapeutics

(Get Rating)

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.